The success of antibody therapeutics begins with one critical decision: choosing the right target. However, traditional target discovery approaches often rely on fragmented data, limited biological insight, and time-consuming experimental validation, resulting in high failure rates and prolonged development timelines. At CD ComputaBio, we address these challenges through our proprietary AbGenesis™ Platform, an AI-powered biological intelligence engine designed to transform how therapeutic targets are identified, evaluated, and prioritized. By integrating multi-omics data, advanced machine learning models, and antibody-specific design considerations, we enable our partners to rapidly identify high-confidence, clinically relevant, and developable targets—laying a strong foundation for successful antibody drug development.
| Challenges in Traditional Target Discovery | Our AI-Driven Solutions |
| Fragmented multi-omics data | Unified multi-modal data integration |
| Poor target-disease causality | AI-based causal inference models |
| Lack of tissue/cell specificity | Single-cell & spatial resolution modeling |
| Low translational success | Relevance prediction |
| Correlation ≠ causation | Causal inference modeling |
| Difficult targets (membrane proteins, GPCRs) | Structure-informed target prioritization |
We combine large-scale biological data, advanced AI models, and antibody-centric insights to identify and prioritize targets with the highest therapeutic potential. Our solution is not just another bioinformatics service; it is a paradigm shift. We deploy the AbGenesis™ platform to systematically ingest petabytes of public and proprietary biological data, mapping the complex molecular architecture of diseases. Our approach gives us an antibody/target pair ready for AI optimization and IND-enabling studies. Our AI technology helps answer the questions that matter most to antibody developers:
We offer a transparent, systematic, and highly collaborative workflow. Every step is designed to de-risk the process and build confidence in the final target selection.
The process begins by aggregating relevant multi-omics datasets (transcriptomics, proteomics, epigenomics) specific to the client's disease of interest. Our platform cleans, normalizes, and harmonizes disparate data types into a unified, machine-readable format, ensuring high signal-to-noise ratios.
Using the harmonized data, we construct dynamic biological networks and knowledge graphs. We map out the specific molecular pathophysiology of the disease, identifying the key signaling pathways, metabolic shifts, and immune evasion mechanisms at play.
Our AI models screen millions of potential data points across the constructed networks to identify potential targets. This includes uncovering novel disease drivers, identifying synthetic lethal pairs, and discovering unique splice variants or post-translational modifications specific to the disease state.
The raw list of identified targets is subjected to our rigorous prioritization engine. Targets are scored across dozens of parameters simultaneously, including causal evidence, tissue specificity (to minimize off-target toxicity), expression levels, and genetic validation.
We apply our antibody-centric lens. Through advanced 3D structural modeling and homology analysis, we evaluate whether the target can actually be bound by an antibody. We assess membrane topology, extracellular domain size, glycosylation shielding, and epitope uniqueness.
Computational predictions must be grounded in physical reality. We design and perform a bespoke, highly efficient wet-lab validation experiment, recommending specific in vitro assays, cell lines, and in vivo models to definitively prove the target's biological function and therapeutic potential.
Our AI-driven target discovery platform is versatile and has been successfully applied across a wide range of complex disease areas. By integrating disease-specific multi-omics with our proprietary AbGenesis™ algorithms, we address the unique biological challenges inherent to different therapeutic fields.
| Therapeutic Area | AI-Driven Target Focus | Strategic Value & Antibody Modality Support |
| Oncology | Tumor-Specific Antigens (TSAs), novel immune checkpoint regulators, and tumor microenvironment (TME) modulators. | Identifies targets with high internalizing rates for ADCs, and unique surface markers for Bispecifics and CAR-T therapies to minimize off-tumor toxicity. |
| Autoimmune & Inflammatory | Master regulators of pathogenic T-cell/B-cell subsets and tissue-specific inflammatory cytokines. | Pinpoints localized drivers of inflammation to enable therapies that avoid global systemic immunosuppression. |
| Neurological Disorders | Brain-specific surface receptors and novel blood-brain barrier (BBB) transcytosis shuttles. | Facilitates the delivery of therapeutic antibodies across the BBB for high-impact targets in Alzheimer's, Parkinson's, and ALS. |
| Infectious Diseases | Highly conserved viral/bacterial epitopes and host-dependency factors. | Accelerates the discovery of broadly neutralizing antibodies against rapidly mutating pathogens and emerging viral threats. |
| Metabolic & Fibrotic Diseases | Surface receptors driving myofibroblast activation and metabolic dysregulation nodes. | Uncovers novel points of intervention for complex multi-organ diseases such as NASH/MASH, CKD, and idiopathic pulmonary fibrosis. |
| Rare & Orphan Diseases | Genetic drivers with specific protein-level manifestations and receptor-mediated signaling defects. | Leverages AI to find actionable targets in "data-sparse" environments, providing hope for ultra-rare conditions with high unmet needs. |
After AI-driven target identification and prioritization, experimental validation is essential to confirm biological relevance and ensure downstream therapeutic success. At CD ComputaBio, we integrate wet-lab validation strategies to systematically evaluate target expression, function, and antibody readiness.
Confirming target presence and disease specificity
We validate whether identified targets are expressed in the relevant tissues, cell types, and disease contexts, ensuring biological and clinical relevance.
Key approaches include:
Outcome:
✓ Verified target expression patterns
✓ Disease-specific and tissue-specific expression profiles
Establishing the role of targets in disease mechanisms
We assess whether the target plays a causal or regulatory role in disease progression, providing strong evidence for therapeutic relevance.
Key approaches include:
Outcome:
✓ Functional confirmation of target involvement
✓ Identification of disease-driving or regulatory targets
Assessing suitability for antibody-based therapeutics
Beyond biological relevance, we evaluate whether targets are practically actionable for antibody development, a critical differentiator of our platform.
Key approaches include:
Outcome:
✓ Identification of antibody-accessible targets
✓ Reduced downstream development risk
✓ Prioritized targets ready for antibody discovery
By combining AI-driven discovery with rigorous experimental validation, we ensure that identified targets are not only biologically relevant but also antibody-ready.
| Target Shortlist | Target Biology Report | Expression & Specificity Profile |
|---|---|---|
| Ranked, high-confidence targets based on AI-driven multi-parameter scoring and integrated multi-omics data | Comprehensive analysis of target function, disease relevance, and regulatory pathways | Tissue- and cell-type-specific expression patterns, including disease vs normal comparison |
| ✓ Multi-omics integration ✓ Clear prioritization logic |
✓ Pathway & mechanism insights ✓ Literature-supported evidence |
✓ Disease vs normal expression ✓ Single-cell resolution (if applicable) |
| → Focus resources on the most promising candidates | → Build a strong biological foundation | → Reduce off-target risks |
| Antibody Readiness Assessment | Risk & Developability Assessment | Experimental Validation Strategy |
| Evaluation of target suitability for antibody-based therapeutics | Early identification of safety, druggability, and developability risks | Clear roadmap for wet-lab validation and experimental confirmation |
| ✓ Surface accessibility analysis ✓ Epitope feasibility ✓ Target selectivity profiling |
✓ Safety & off-target risk evaluation ✓ Druggability assessment ✓ Developability insights |
✓ Assay recommendations ✓ Model system selection ✓ Prioritized validation plan |
| → Ensure antibody compatibility and feasibility | → De-risk downstream development | → Accelerate transition to experimental validation |
| Optional Wet-Lab Validation Services (Optional) | ||
| Experimental validation services including expression confirmation, functional assays, and feasibility testing ✓ qPCR / Flow cytometry / IHC ✓ CRISPR / Functional assays |
||
| → End-to-end support from discovery to validation | ||
Choosing the right partner is critical for successful target discovery. CD ComputaBio offers a unique combination of AI expertise and antibody development insight.
Our goal is not just to identify targets—but to deliver targets that work in real-world drug development pipelines.
| Case Study 1: Oncology Target Discovery | Case Study 2: Autoimmune Disease Target Discovery |
|
Background: A biotech company sought to identify novel tumor-specific targets for antibody therapy in solid tumors. Solution: Using the AbGenesis™ Platform, we integrated multi-omics and single-cell data to model tumor heterogeneity and identify candidate targets. Result:
|
Background: A client aimed to discover targets for modulating immune response in autoimmune disorders. Solution: We applied AI-driven network analysis to identify key immune regulatory nodes and pathways. Result:
|
AI is fundamentally transforming how therapeutic targets are discovered. By combining biological data, advanced AI models, and antibody-specific insights, CD ComputaBio enables faster, more accurate, and more reliable target discovery. With our AbGenesis™ Platform, you can reduce risk, accelerate timelines, and increase the probability of success in antibody drug development. Contact us today to accelerate your target discovery program.
